Effectiveness of piracetam in cortical myoclonus
The DOI matches its Crossref record.
Abstract
Twenty‐one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo‐controlled double‐blind crossover trial of piracetam (2.4– 16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14‐ day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double‐blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Myoclonus: current concepts and recent advances
Caviness, J. N., & Brown, P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00880-4 · Cited by 375
Self-citationPiracetam: A Review of Pharmacological Properties and Clinical Uses
Winblad, B. (2005) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00268.x · Cited by 317
Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255
Löscher, W., & Schmidt, D. (1994) · Epilepsy Research · doi:10.1016/0920-1211(94)90012-4 · Cited by 221
Kasteleijn-Nolst Trenité, D. G. A., Marescaux, C., Stodieck, S., Edelbroek, P. M., & Oosting, J. (1996) · Epilepsy Research · doi:10.1016/s0920-1211(96)00031-9 · Cited by 183
“Piracetam has been reported not only to lessen cognitive disturbances but also to reduce myoclonic jerks [4,5].”
Treatment of Acute Ischemic Stroke With Piracetam
De Deyn, P. P., De Reuck, J., Deberdt, W., Vlietinck, R., & Orgogozo, J.-M. (1997) · Stroke · doi:10.1161/01.str.28.12.2347 · Cited by 154
Cortical myoclonus in angelman syndrome
Guerrini, R., Bonanni, P., de Lorey, T. M., Serratosa, J. M., Moncla, A., Malzac, P., Dravet, C., Igvet, M. O., Bureau, M., Genton, P., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400109 · Cited by 142
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
Network dysfunction in α‐synuclein transgenic mice and human Lewy body dementia
Morris, M., Sanchez, P. E., Verret, L., Beagle, A. J., Guo, W., Dubal, D., Ranasinghe, K. G., Koyama, A., Ho, K., Yu, G., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.257 · Cited by 61
Metadata
- Authors
- Brown, P., Steiger, M. J., Thompson, P. D., Rothwell, J. C., Day, B. L., Salama, M., Waegemans, T., & Marsden, C. D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1993-01
- Volume
- 8
- Issue
- 1
- Pages
- 63-68
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1988173183
- Cited by
- 93
- References
- 0
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.